Health Care • Biotechnology: Electromedical & Electrotherapeutic Apparatus
$1.14 ▲ +0.00
(0.00%)
MKT CAP: $102.8M • VOL: 195.1K
52W L $1 52W H $2
ROARABLE / RQD
E • 34/100
PIOTROSKI
3 / 9
VANI // SEC EDGAR XBRL STANDARDIZED FINANCIAL STATEMENTS (FA <GO>)
| LINE ITEM (USD / %) | FY 2025
FILED 2025-12-31 | FY 2024
FILED 2024-12-31 | FY 2023
FILED 2023-12-31 |
|---|---|---|---|
| Revenue (Total Sales) | $0 | $0 | $0 |
| YoY Revenue Growth % | — | — | — |
| Gross Profit | — | — | — |
| Gross Margin % | — | — | — |
| Research & Development (R&D) | — | — | — |
| Operating Income (EBIT) | -$27.6M | -$24.7M | -$27.0M |
| Operating Margin % | — | — | — |
| Net Income (GAAP) | $26.6M | $23.5M | $25.7M |
| EBITDA (Normalized) | -$26.6M | -$24.2M | — |
| Diluted EPS ($/sh) | — | — | — |
| Operating Cash Flow (OCF) | -$24.3M | -$20.8M | -$23.7M |
| Capital Expenditures (CapEx) | $1.2M | $556.0K | — |
| Free Cash Flow (FCF) | -$25.5M | -$21.3M | -$23.7M |
| FCF Margin % | — | — | — |
| Return on Invested Capital (ROIC %) | -45.0% | -45.0% | — |
| Cash & Short-Term Equivalents | $16.2M | $18.4M | — |
| Total Debt (Short + Long Term) | — | — | — |
| Total Stockholders' Equity | $15.7M | $17.6M | — |
NO QUARTERLY 10-Q XBRL STATEMENTS AVAILABLE IN CURRENT CACHE FOR VANI.